Pay in 4 interest-free payments of $33.00 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
PubMed Central PMCID: PMC3529962
Smiles: CCN(CCC)C(=O)C1=CC2=CC=C3C(NC=C(C3=O)[N+]([O-])=O)=C2N=C1
Preclinical studies have demonstrated that the compound promotes the function and survival of neurons and other cell types under disease-relevant stress conditions through interactions with the mitochondrial permeability transition pore (mPTP)
Darapladib - CAS# 356057-34-6 Catalog No.:M10558-2 PubMed Central PMCID: PMC3529962Darapladib, also known as SB 480848, is a reversible lipoprotein associated phospholipase A2 (Lp PLA2) inhibitor with IC50 of 0. 25 nM, which is in Phase 3 trials. Recent studies showed that risk of major coronary events not reduced by darapladib therapy. In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. Product
US$ 29.00
US$ 20.62
US$ 43.14
US$ 28.74
US$ 28.74
US$ 21.54
US$ 44.95
US$ 23.94
US$ 79.95
US$ 59.95
US$ 47.93